DLK1 and pachyonychia congenita: Taken together, the findings here discussed indicate that DLK1-DIO3 miRNAs are attractive therapeutic targets to block the tumor–stroma interactions in PC patients and demonstrate a role for miR-423-5p in PC chemoresistance.